Art. -Nr.: HY-W013053

Dibenz[a,h]anthracene

Name: Dibenz[a,h]anthracene
Brand: MedChemExpress
SKU: HY-W013053
Price: 25.00 USD
Availability: InStock
Rating: 5 (1 reviews)

(Synonyms: DBA; 1,2,5,6-Dibenzanthracene; Benzo[k]tetraphene)

Kundenbewertung

Based on 1 Customer Validation

Dibenz[a,h]anthracene (DBA) is an orally active polycyclic aromatic hydrocarbon, a by-product of incomplete combustion of organic matter, a potent carcinogen, and an agonist of AhR. Dibenz[a,h]anthracene induces dose-dependent increases in DNA adduct formation and lacZ mutation frequency. Dibenz[a,h]anthracene upregulates St3gal5. Dibenz[a,h]anthracene can be used in cancer-related research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.0%
CAS. Nr.: 53-70-3
Formel: C₂₂H₁₄
Molecular Weight:278.35

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Dibenz[a,h]anthracene Chemical Structure

CAS. Nr.: 53-70-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen :

In Vitro

Dibenz[a,h]anthracene potently activates AhR in H1L1.1c2 mouse hepatocellular carcinoma cells, with a K_m of 0.082 ng/mL and an asymptotic maximum net luciferase response of 10.0 × 10³ RLU^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Dibenz[a,h]anthracene (6.25-25 mg/kg/day; intragastric administration; daily; for consecutive 28 days) induces dose-dependent genotoxicity in male Muta mice, including promoting hepatic DNA adduct formation and lacZ transgene mutation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Muta™Mouse (transgenic strain 40.6) (male, 10 weeks old)^[1]
Dosage:

6.25-25 mg/kg/day
Administration:

p.o.; daily; 28 days
Result:

Increased mean Ki67 index to 0.0205 (P < 0.02) at 6.25 mg/kg/day, 0.0178 (not significant) at 12.5 mg/kg/day, and 0.0126 (not significant) at 25 mg/kg/day, compared to control 0.0072.
Induced dose-dependent increase in hepatic DNA adducts (ANOVA: P < 0.0001), with levels reaching 26.4 adducts per 10⁸ nucleotides at 25 mg/kg/day; no adducts detected in controls.
Caused dose-dependent increase in lacZ mutant frequency (chi-square analysis: P < 0.0001), with significant elevations at 12.5 mg/kg/day (P < 0.0001) and 25 mg/kg/day (P < 0.0001); 25 mg/kg/day dose resulted in a mutant frequency 3.7-fold above control, with 20.48 mutants per 10⁵ recovered transgene copies.
Observed strong correlation between adduct frequency and lacZ mutant frequency (r = 0.740, P < 0.05).
Up-regulated 19 genes and down-regulated 22 genes (FDR-adjusted P ≤ 0.05; fold change ≥ 1.5) at 6.25 mg/kg/day; up-regulated 13 genes and down-regulated 32 genes (FDR-adjusted P ≤ 0.05; fold change ≥ 1.5) at 12.5 mg/kg/day; up-regulated 135 genes and down-regulated 104 genes (FDR-adjusted P ≤ 0.05; fold change ≥ 1.5) at 25 mg/kg/day, perturbing pathways including circadian rhythm, glucose metabolism, lipid metabolism, cell cycle, apoptosis, and immune response.
Induced dose-dependent up-regulation of miR-34a, with fold changes of 1.56 (FDR P = 0.09) at 6.25 mg/kg/day, 2.94 (FDR P = 0.00) at 12.5 mg/kg/day, and 3.69 (FDR P = 0.00) at 25 mg/kg/day; RT-PCR confirmed significant up-regulation at all doses (P < 0.05).

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 53-70-3
Appearance Solid
Molecular Weight 278.35
Formel C₂₂H₁₄
Color White to light yellow
SMILES

C12=CC=CC=C1C3=CC(C=CC4=CC=CC=C45)=C5C=C3C=C2
Synonyms

DBA; 1,2,5,6-Dibenzanthracene; Benzo[k]tetraphene
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 5 mg/mL (17.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.5926 mL

17.9630 mL

35.9260 mL

5 mM

0.7185 mL

3.5926 mL

7.1852 mL

10 mM

0.3593 mL

1.7963 mL

3.5926 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 0.5 mg/mL (1.80 mM); Clear solution

This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (623 KB)
- English - EN (623 KB)
- Français - FR (623 KB)
- Deutsch - DE (623 KB)
- Norwegian - NO (623 KB)
- Español - ES (623 KB)
- Swedish - SV (623 KB)
- Italian - IT (623 KB)
- Korean - KR (623 KB)
- Portuguese - PT (623 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Malik A I, et al. Hepatic genotoxicity and toxicogenomic responses in Muta™ Mouse males treated with dibenz [a, h] anthracene[J]. Mutagenesis, 2013, 28(5): 543-554.

[2]. Platt KL, et al. Stereoselective metabolism of dibenz(a,h)anthracene to trans-dihydrodiols and their activation to bacterial mutagens. Environ Health Perspect. 1990;88:37-41. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.5926 mL	17.9630 mL	35.9260 mL	89.8150 mL
	5 mM	0.7185 mL	3.5926 mL	7.1852 mL	17.9630 mL
	10 mM	0.3593 mL	1.7963 mL	3.5926 mL	8.9815 mL
	15 mM	0.2395 mL	1.1975 mL	2.3951 mL	5.9877 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Dibenz[a,h]anthracene

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen